BridgeBio's Encaleret Scores Major Win in Rare Calcium Disorder Trial

BridgeBio Pharma (BBIO) announces positive phase 3 results for encaleret in ADH1, showing 76% response rate. FDA filing planned for first half of 2026 alongside BBP-418 submission.